US 11,654,190 B2
Immunogenic composition
Amirreza Faridmoayer, Schlieren (CH); Rainer Follador, Schlieren (CH); Stefan Jochen Kemmler, Schlieren (CH); Michael Thomas Kowarik, Schlieren (CH); Gerd Martin Lipowsky, Schlieren (CH); Gerald Johann Posch, Schlieren (CH); and Fabio Serventi, Schlieren (CH)
Assigned to GLAXOSMITHKLINE BIOLOGICALS SA, Rixensart (BE)
Appl. No. 16/620,911
Filed by GLAXOSMITHKLINE BIOLOGICALS SA, Rixensart (BE)
PCT Filed Jul. 17, 2018, PCT No. PCT/EP2018/069354
§ 371(c)(1), (2) Date Dec. 10, 2019,
PCT Pub. No. WO2019/016187, PCT Pub. Date Jan. 24, 2019.
Claims priority of application No. 1711635 (GB), filed on Jul. 19, 2017.
Prior Publication US 2020/0179505 A1, Jun. 11, 2020
Int. Cl. A61K 39/09 (2006.01); C12P 19/04 (2006.01); C12P 21/00 (2006.01)
CPC A61K 39/092 (2013.01) [C12P 19/04 (2013.01); C12P 21/005 (2013.01)] 5 Claims
OG exemplary drawing
 
1. A pneumococcal saccharide comprising one or more repeat unit(s) →4)-β-D-Glcp-(1→3)-[[α-L-Rhap-(1→2)]-[Gro-(2→P→3)]-β-D-Galp-(1→4)]-β-L-Rhap-(1→conjugated to a carrier protein, wherein the pneumococcal saccharide comprising less than 100 repeat units; wherein the molecular weight of the conjugate is 30-220 kDa;
wherein the pneumococcal saccharide is conjugated to a carrier protein selected from CRM197, Diphtheria toxoid, tetanus toxoid, detoxified exotoxin A from P. aeruginosa, detoxified hemolysin A of S. aureus, clumping factor A, clumping factor B, E. coli FimH, E. coli FimHC, E. coli heat labile enterotoxin, detoxified variants of E. coli heat labile enterotoxin, Cholera toxin B subunit (CTB), cholera toxin, detoxified variants of cholera toxin, E. coli sat protein, the passenger domain of E. coli sat protein, C. jejuni AcrA, C. jejuni natural glycoproteins, S. pneumoniae pneumolysin, S. pneumoniae NOX, S. pneumoniae PspA, S. pneumoniae PcpA, S. pneumoniae PhtD, S. pneumoniae PhtE, S. pneumoniae ply (e.g. detoxified ply), or S. pneumoniae LytB;
wherein the pneumococcal saccharide is a bioconjugate having a structure;
(B)n-A→
wherein A is an oligosaccharide containing at least 2, 3, 4, 5, 6, 7 or 8 monosaccharides, with a hexose monosaccharide derivative at the reducing end (indicated by the arrow in the diagram);
wherein the hexose monosaccharide derivative is N-acetylglucosamine (GlcNAc), N-acetylgalactoseamine (GalNAc), 2,4-Diacetamido-2,4,6-trideoxyhexose (DATDH), N-acetylfucoseamine (FucNAc), or N-acetylquinovosamine (QuiNAc) (e.g. N-acetylglucosamine (GlcNAc));
wherein B is an oligosaccharide repeat unit →4)-β-D-Glcp-(1→3)-[[α-L-Rhap-(1→2)]-[Gro-(2→P→3)]-β-D-Galp-(1→4)]-β-L-Rhap-(1→; and
wherein n is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or at least 20.